Back to all MindMaze Therapeutics Holding SA press releases
MindMaze Therapeutics Holding SA
- OTCQB:MMTZF
- SIX:MMTX
MindMaze Reports First SwissNeuroRehab Enrolments and Launch of French Stroke Study
Published
At a glance
- Company
- MindMaze Therapeutics Holding SA
- Listings
- OTCQB:MMTZF, SIX:MMTX
- Announcement type
- Operational update
- Published
- Source announcement
- eqs-news.com
| Measure | Figure | Period |
|---|---|---|
| Active training | 300 minutes | per week |
| Inpatient phase | 4-6 week | Not stated |
| Outpatient/home phase | 8-12 week | Not stated |
| Follow-up | 15 months | from inclusion |
Figures are quoted from this announcement and selected automatically.
FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices
Announcement Summary
MindMaze Therapeutics Holding SA (SIX: MMTX) announced developments in two European neurorehabilitation studies.
- SwissNeuroRehab enrolled its first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study.
- It is a CHF 11.2 million consortium study spanning six major Swiss centers.
- The protocol targets 300 minutes training per week, with 4-6 week inpatient, 8-12 week outpatient/home, and follow-up at 15 months from inclusion.
- CHUV sponsors the study; it is funded within the Innosuisse Flagship Program and registered on ClinicalTrials.gov as NCT07427511.
- Recruitment is active at Lausanne University Hospital (CHUV), Institution de Lavigny, Rehaklinik Valens, Swiss Rehabilitation Sàrl, Universitätsspital Zürich, and Lake Lucerne Institute.
MindMaze also launched REACT-AVC at Hospices Civils de Lyon, the first clinical study of Neurorehab4EU, focused on early outpatient and home-based stroke rehabilitation and evidence for reimbursement in France.
Investor FAQs
Source announcement
- Company
- MindMaze Therapeutics Holding SA
- Title
- MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe
- Published
- Source site
- eqs-news.com
Read the source announcement on eqs-news.com
FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.
Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.
Read the original press release
Full text as published, unedited.